13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001952142
Total reported value
$580.5M
$580.5M
75 檔
29.9%
At the close of Q4 2025, Stempoint Capital LP disclosed equity holdings valued at approximately $580.5M, spread across 75 reported holdings.
Stempoint Capital LP executed strategic sector rebalancing during Q4 2025, establishing 32 new positions while fully exiting 37 holdings and trimming 16 positions.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, SRRK, 260) accounted for 29.9% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 9.06% | -0.18% | +135.63% | |
| 2 | SRRK | Scholar Rock Holding CORP | Stock-Other | 6.78% | -7.59% | +56.31% | |
| 3 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 4.95% | — | +48.46% | |
| 4 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 4.83% | -5.45% | EXIT | |
| 5 | GPCR | Structure Therapeutics Inc | Stock-Other | 4.19% | -1.50% | +171.44% | |
| 6 | ACLXGBX | Arcellx Inc | Stock-Other | 3.72% | — | +2825.98% | |
| 7 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 3.60% | +0.08% | -76.97% | |
| 8 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.97% | — | EXIT | |
| 9 | TWST | Twist Bioscience CORP | Stock-Other | 2.82% | -0.39% | EXIT | |
| 10 | IMVT | Immunovant Inc | Stock-Other | 2.81% | -1.76% | -64.94% | |
| 11 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.80% | -1.76% | EXIT | |
| 12 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.68% | -0.78% | +81.29% | |
| 13 | SRZN | Surrozen Inc | Stock-Other | 2.17% | -0.21% | -13.13% | |
| 14 | CELC | Celcuity Inc | Stock-Other | 2.02% | +0.46% | -13.44% | |
| 15 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.80% | +0.03% | +83.45% | |
| 16 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.77% | — | +116.11% | |
| 17 | ADPT | Adaptive Biotechnologies | Stock-Other | 1.69% | — | — | |
| 18 | PALI | Palisade Bio Inc | Stock-Other | 1.69% | — | — | |
| 19 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.60% | -0.53% | — | |
| 20 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.54% | -1.75% | EXIT | |
| 21 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.30% | — | — | |
| 22 | NKTR | Nektar Therapeutics | Stock-Other | 1.29% | — | +235.10% | |
| 23 | JNJ | Johnson & Johnson | Stock-Healthcare | 1.24% | -0.72% | EXIT | |
| 24 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.19% | -1.57% | EXIT | |
| 25 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.17% | -0.59% | +104.11% | |
| 26 | CLPT | Clearpoint Neuro Inc | Stock-Other | 1.13% | — | +2793.87% | |
| 27 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.12% | -1.42% | -45.44% | |
| 28 | EYPT | Eyepoint Inc | Stock-Other | 1.11% | -1.17% | — | |
| 29 | ✓ | Immatics NV | Stock-Other | 1.10% | — | — | |
| 30 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.09% | — | +45.41% | |
| 31 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.08% | — | -35.57% | |
| 32 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.06% | -1.32% | — | |
| 33 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.04% | — | — | |
| 34 | INCY | Incyte CORP | Stock-Healthcare | 1.04% | — | +40.41% | |
| 35 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.96% | — | -56.52% | |
| 36 | ASMB | Assembly Biosciences Inc | Stock-Other | 0.91% | -0.18% | +137.00% | |
| 37 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.89% | — | — | |
| 38 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.89% | -1.12% | +23.93% | |
| 39 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.88% | — | — | |
| 40 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.86% | — | +13.93% | |
| 41 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.85% | -0.16% | -66.54% | |
| 42 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.82% | — | — | |
| 43 | ABUS | Arbutus Biopharma CORP | Stock-Other | 0.81% | — | +228.49% | |
| 44 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.79% | — | — | |
| 45 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 46 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 0.62% | -0.67% | EXIT | |
| 47 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 0.61% | +0.19% | +243.99% | |
| 48 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.56% | +2.00% | +91.59% | |
| 49 | ASND | Ascendis Pharma A/S | Stock-Other | 0.54% | — | -2.03% | |
| 50 | RGEN | Repligen CORP | Stock-Healthcare | 0.44% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | +6.2% | +135.63% | Add |
| 2 | ACLXGBX | Arcellx Inc | +3.5% | +2825.98% | Add |
| 3 | GPCR | Structure Therapeutics Inc | +3.5% | +171.44% | Add |
| 4 | 430 | Terns Pharmaceuticals Inc | +2.8% | +378.92% | Add |
| 5 | DYN | Dyne Therapeutics Inc | +1.6% | +75.98% | Add |
| 6 | 260 | Centessa Pharmaceuticals-adr | +1.6% | +48.46% | Add |
| 7 | SRRK | Scholar Rock Holding CORP | +1.4% | +56.31% | Add |
| 8 | XENE | Xenon Pharmaceuticals Inc | +1.1% | +81.29% | Add |
| 9 | CLPT | Clearpoint Neuro Inc | +1.1% | +2793.87% | Add |
| 10 | MDGL | Madrigal Pharmaceuticals Inc | +1% | +116.11% | Add |
| 11 | NKTR | Nektar Therapeutics | +0.7% | +235.10% | Add |
| 12 | CELC | Celcuity Inc | +0.7% | -13.44% | Trim |
| 13 | ABUS | Arbutus Biopharma CORP | +0.6% | +228.49% | Add |
| 14 | SNDX | Syndax Pharmaceuticals Inc | +0.6% | -8.65% | Trim |
| 15 | MLYS | Mineralys Therapeutics Inc | +0.6% | +83.45% | Add |
| 16 | ASMB | Assembly Biosciences Inc | +0.6% | +137.00% | Add |
| 17 | WHWK | Whitehawk Therapeutics Inc | +0.5% | +243.99% | Add |
| 18 | AMLX | Amylyx Pharmaceuticals Inc | +0.4% | +104.11% | Add |
| 19 | IVVD | Invivyd Inc | +0.4% | +255.27% | Add |
| 20 | SRZN | Surrozen Inc | +0.3% | -13.13% | Trim |
| 21 | IVA | Inventiva SA - Adr | +0.3% | +1415.84% | Add |
| 22 | INCY | Incyte CORP | +0.3% | +40.41% | Add |
| 23 | OCUL | Ocular Therapeutix Inc | +0.3% | +45.41% | Add |
| 24 | PTGX | Protagonist Therapeutics Inc | +0.3% | +23.93% | Add |
| 25 | MGTX | MeiraGTx Holdings plc | +0.3% | +251.45% | Add |
| 26 | XFOR | X4 Pharmaceuticals Inc | +0.2% | +61.77% | Add |
| 27 | DNTH | Dianthus Therapeutics Inc | +0.2% | +91.59% | Add |
| 28 | TRVI | Trevi Therapeutics Inc | +0.2% | +13.93% | Add |
| 29 | MBX | Mbx Biosciences Inc | +0.2% | +4.74% | Add |
| 30 | ✓ | Adc Therapeutics SA | +0.1% | +77.41% | Add |
| 31 | ASND | Ascendis Pharma A/S | -0.1% | -2.03% | Trim |
| 32 | BBOT | Bridgebio Oncology Therapeut | -0.2% | -53.64% | Trim |
| 33 | TSHA | Taysha Gene Therapies Inc | -0.4% | -78.31% | Trim |
| 34 | NAMS | NewAmsterdam Pharma Company N.V. | -0.4% | -51.45% | Trim |
| 35 | ARQT | Arcutis Biotherapeutics Inc | -0.4% | -45.44% | Trim |
| 36 | RYTM | Rhythm Pharmaceuticals Inc | -0.8% | -35.57% | Trim |
| 37 | RVMD | Revolution Medicines Inc | -0.9% | -66.54% | Trim |
| 38 | IDYA | Ideaya Biosciences Inc | -1.1% | -56.52% | Trim |
| 39 | VTGN | Vistagen Therapeutics Inc | -1.5% | -75.22% | Trim |
| 40 | IMVT | Immunovant Inc | -2.3% | -64.94% | Trim |
| 41 | DNLI | Denali Therapeutics Inc | -3.9% | -75.84% | Trim |
| 42 | QURE | uniQure N.V. | -5.9% | -91.67% | Trim |
| 43 | ROIV | Roivant Sciences Ltd. | -9.1% | -76.97% | Trim |
| 44 | BHVN | Biohaven Ltd. | — | EXIT | Sold out |
| 45 | TWST | Twist Bioscience CORP | — | NEW | New buy |
| 46 | WVE | Wave Life Sciences Ltd. | — | EXIT | Sold out |
| 47 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 48 | ADPT | Adaptive Biotechnologies | — | NEW | New buy |
| 49 | PALI | Palisade Bio Inc | — | NEW | New buy |
| 50 | CYTK | Cytokinetics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Stempoint Capital LP reported a total U.S. public equity portfolio value of $580.5M across 75 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
TWST
市值: $16.4M
Top Position Liquidated / Trimmed
BHVN
前期市值: $16.5M
During Q4 2025, Stempoint Capital LP's top holdings by market value included ABVX (9.1%)、SRRK (6.8%)、260 (5.0%). The largest single position, ABVX, represented 9.1% of total portfolio value.
In Q4 2025, Stempoint Capital LP made 112 total portfolio adjustments, initiating 32 new buys, adding to 27 positions, trimming 16 holdings, and fully liquidating 37 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.